Allergy Therapeutics (AGY.L)

Executive Summary

Allergy Therapeutics is a UK-based specialty biopharmaceutical company pioneering aluminium-free allergy immunotherapy (AIT) through its proprietary MicroCrystalline Tyrosine (MCT) adjuvant platform. The company’s ultra-short-course vaccines require only 4–6 injections over 3–5 weeks, compared to conventional 50–100 injection regimens, offering significant patient convenience and compliance advantages. Operating across 19 European markets with a strong presence in Germany, Allergy Therapeutics has a portfolio of five commercial products and a pipeline focused on respiratory and food allergies. The company trades on the London Stock Exchange under ticker AGY.L. The company is well-positioned to capitalize on the growing global allergy treatment market, driven by increasing prevalence and patient demand for shorter, more effective therapies. Near-term value drivers include regulatory submissions for its lead grass and birch pollen vaccines in Europe, as well as potential partnerships leveraging its MCT adjuvant technology. While the company faces competition from other AIT developers and relies on successful clinical and regulatory outcomes, its differentiated platform and established commercial footprint in Europe provide a solid foundation for growth. The next 12–18 months are critical as key data readouts and approval decisions approach.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for Grass MATA MPL in seasonal allergic rhinitis60% success
• Q1 2027EMA approval decision for Pollinex Quattro Birch pollen vaccine70% success
• Q2 2026Licensing partnership for MCT adjuvant platform with major pharma50% success